Last updated on September 2020

Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Acute Myocardial Infarction
  • Age: Between 18 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  1. Male or female patients 18 years of age.
  2. Diagnosis of spontaneous AMI based on the universal MI definition with randomization to occur between 12 hours and 7 days after index event presentation. (patients with spontaneous MI event determined to be secondary to another medical condition such as anemia, hypotension, or arrhythmia OR thought to be caused by coronary vasospasm with document normal coronary arteries are not eligible; patients with clinical presentation thought to be related to Takotsubo cardiomyopathy are also not eligible)
  3. Evidence of LV systolic dysfunction and/or pulmonary congestion requiring intravenous treatment associated with the index MI event defined as:
    • LVEF 40% after index MI presentation and prior to randomization and/or
    • Pulmonary congestion requiring intravenous treatment with diuretics, vasodilators, vasopressors and/or inotropes, during the index hospitalization
  4. At least one of the following 8 risk factors:
    • Age 70 years
    • eGFR <60 mL/min/1.73 m^2 based on MDRD formula at screening visit
    • Type I or II diabetes mellitus
    • Documented history of prior MI
    • Atrial fibrillation as noted by ECG, associated with index MI
    • LVEF <30% associated with index MI
    • Worst Killip class III or IV associated with index MI requiring intravenous treatment
    • STEMI without reperfusion therapy within the first 24 hours after presentation
  5. Hemodynamically stable defined as:
    • SBP 100 mmHg at randomization for patients who received ACEi/ARB during the last 24 hours prior to randomization
    • SBP 110 mmHg at randomization for patients who did not receive ACEi/ARB during the last 24 hours prior to randomization
    • No IV treatment with diuretics, vasodilators, vasopressors and/or inotropes during the 24 hours prior to randomization

Key Exclusion Criteria:

  1. Known history of chronic HF prior to randomization
  2. Cardiogenic shock within the last 24 hours prior to randomization
  3. Persistent clinical HF at the time of randomization
  4. Coronary artery bypass graft (CABG) performed or planned for index MI
  5. Clinically significant right ventricular MI as index MI
  6. Symptomatic hypotension at screening or randomization
  7. Patients with a known history of angioedema
  8. Stroke or transient ischemic attack within one month prior to randomization
  9. Known or suspected bilateral renal artery stenosis
  10. Clinically significant obstructive cardiomyopathy
  11. Open-heart surgery performed within one month prior to randomization or planned cardiac surgery w/in the 3 months prior to randomization
  12. eGFR < 30 ml/min/1.73 m^2 as measured by MDRD at screening
  13. Serum potassium > 5.2 mmol /L (or equivalent plasma potassium value) at randomization
  14. Known hepatic impairment (as evidenced by total bilirubin > 3.0 mg/dL or increased ammonia levels, if performed), or history of cirrhosis with evidence of portal hypertension such as esophageal varices
  15. Previous use of LCZ696
  16. History of malignancy of any organ system (other than localized basal cell carcinoma of the skin) within the past 3 years with a life expectancy of less than 1year.
  17. History of hypersensitivity to the study drugs or drugs of similar chemical classes or known intolerance or contraindications to study drugs or drugs of similar chemical classes including ACE inhibitors, ARB or NEP inhibitors
  18. Pregnant or nursing women or women of child-bearing potential unless they are using highly effective methods of contraception

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.